Tagged with ess

Lilly A recent arrival from China, Lilly’s Turkey MD Daniel Lucas assesses the country’s healthcare system and raises key questions about the sustainability of the system at large going forward, and the authorities’ approach to reform. You came to Turkey in October after more than four years in China. What is your…

MSD MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy and incentivizing CRM use to improve operational efficiencies. You took over last year as managing director of MSD Turkey, after…

GSK GSK’s VP and Area GM Pharmaceuticals, Turkey and Caucasus, and chairman of Turkey’s innovative pharmaceutical association, discusses the effectiveness of the government’s current strategy for reducing the trade deficit in the pharmaceutical industry, and the need for the industry and government to approach all discussions with a partnership mentality. Do…

Chiesi Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government to clarify the incentives that have been discussed? The healthcare system in Turkey has undergone the largest transition in its…

Biocodex Biocodex’s new general manager gives an overview of the affiliates ‘new deal’ program, and how the company has adjusted its approach to better fit the contemporary Turkish environment. What attracted you to Biocodex Turkey? What are your impressions of the business so far? Biocodex made the right decision in starting…

Daiichi Sankyo The general manager of Daiichi Sankyo Turkey discusses his affiliate’s expansion into a regional hub, current strategies for growth in the Turkish market, and the keys behind his affiliates multiple ‘great place to work’ awards.  In 2012, you had made it a goal to develop the Turkish affiliate into a regional…

Ferring The general manager of a speciality biopharma business challenges lawmakers to regard health spending not as a cost but as an investment and reveals how women’s healthcare and fertility treatment can become showcase examples in making Romanian healthcare sustainable. Back in 2011, when we asked you about Ferring’s priorities in…

association The executive director of the German Chamber of Commerce in Romania explains why German companies are deeply embedded in the Romanian market, why the country should be seriously considered as an investment opportunity into Southeast Europe and how the local healthcare system is in need of extra funding, with public…

law firm One of the original market builders of the commercial law practice in Romania analyses the state of in-country legal firms in catering to the evolving needs of pharmaceutical industry players in a rapidly and radically transforming regulatory landscape. An expert in privatisation, he also explains why attempts to inject market…

Pfizer One of the new cohort of country managers speaks out about Romania’s blossoming potential as a manufacturing hub and explains in detail how his firm is diverting product lines form elsewhere in Europe and relocating them in Cluj so as to exploit what he sees as a real competitive advantage.…

association PReMA’s CEO discusses the association’s role within the industry as an organization that is improving the healthcare system in Thailand and on helping companies in the pharmaceutical industry bring innovation and high quality productsn to Thailand. You were recently appointed as the CEO of PReMA. What have been your biggest challenges…

Pfizer The country manager and Global Established Products Business Lead at Pfizer South Africa reveals how the private sector is committed to expanding healthcare for South Africans, why her ambition is to devise different sustainable business models that allow for more affordable medicines, and how Pfizer must crack the emerging market…